Plasmablastic lymphoma: an atypical cutaneous presentation of a rare entity.
Plasmablastic lymphoma is a very rare B-cell lymphoma typically associated with immunosuppression: It occurs primarily in the oral cavity, although some cases were reported in other organs and tissues.To date, only 10 cases of primary cutaneous plasmablastic lymphoma have been described. Clinically, primary cutaneous plasmablastic lymphoma presents as non-specific cutaneous lesions (purple nodules, erythematous infiltrated plaques). In previously described cases, as in this case, histology and immunohistochemistry are required to make the diagnosis. Owing to the rarity of this entity, there is no established therapy, which makes its management an individualized, patient-based decision.
Dermatology Department, Centro Hospitalar do Porto, Porto, Portugal. fernandojrmota@gmail.com.
Fernando
F
Mota
Bruno
B
Mesquita
S
S
Carvalho
André
A
Coelho
Glória
G
Velho
Margarida
M
Lima
Manuela
M
Selores
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D003520:Cyclophosphamide / Q000627:therapeutic use; D017809:Fatal Outcome; D015658:HIV Infections / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D016867:Immunocompromised Host; D007866:Leg; D008297:Male; D000069293:Plasmablastic Lymphoma / Q000150:complications / Q000188:drug therapy / Q000276:immunology / Q000473:pathology*; D011241:Prednisone / Q000627:therapeutic use; D035583:Rare Diseases; D012867:Skin / Q000473:pathology; D014750:Vincristine / Q000627:therapeutic use
D014750:Vincristine; D003520:Cyclophosphamide; D011241:Prednisone